List of works - Andrew Zloza

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

scientific article published oln 16 November 2016

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

scientific article published on 17 February 2018

ACTR-51. CLINICAL EVALUATION OF THE IMIPRIDONE ONC201 IN RECURRENT GLIOBLASTOMA: PREDICTIVE AND PHARMACODYNAMIC BIOMARKER ANALYSES

Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells

scientific article

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy.

scientific article published on 4 November 2015

Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses

scientific article published on 2 December 2013

Beta-catenin signaling mediates CD4 expression on mature CD8+ T cells

scientific article published on 14 July 2010

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease

scientific article

CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus

scientific article published on 06 March 2017

CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression

scientific article published on 31 December 2010

CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells.

scientific article published on 19 March 2012

CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV.

scientific article published on 5 June 2003

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

scientific article published on 7 November 2013

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment

scientific article published on 6 November 2014

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth

scientific article published on 24 June 2016

DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS

scholarly article

Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection

scientific article

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

scientific article published on 13 March 2018

Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor Xenografts

scientific article published on 01 January 2019

Editorial: Tumor Microenvironment and Resistance to Current Therapies

scientific article published on 14 November 2019

Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

scientific article published on 22 March 2017

HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice.

scientific article

HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice

scientific article published on 3 April 2014

HSP70i is a critical component of the immune response leading to vitiligo

scientific article published on 14 November 2011

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

scientific article published on 01 January 2019

High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis

scientific article published on 25 June 2014

IFN-lambda therapy: current status and future perspectives.

scientific article

IFN-λ cancer immunotherapy: new kid on the block

scientific article

IFN-λ: A New Inducer of Local Immunity against Cancer and Infections

scientific article

Immune modulation of HIV replication: relevance to HIV immuno- and neuro-pathogenesis.

scientific article

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

scientific article

Infection: a Cause of and Cure for Cancer.

scientific article published on 5 October 2017

Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment

scientific article published on 08 May 2018

Interferon Lambda: Toward a Dual Role in Cancer

scientific article published on 18 July 2018

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.

scientific article

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

scientific article published on 30 December 2019

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

scientific article published on 18 October 2016

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

scientific article published on 01 December 2018

Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges

scientific article published in February 2014

Multiple populations of T lymphocytes are distinguished by the level of CD4 and CD8 coexpression and require individual consideration.

scientific article published in January 2006

Mutant HSP70 reverses autoimmune depigmentation in vitiligo

scientific article published on February 2013

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

scientific article published on 19 May 2015

NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses

scientific article

Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

scientific article published on 3 November 2017

Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.

scientific article

Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

scientific article published on 6 April 2018

Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.

scientific article published on 11 September 2017

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

scientific article published on 07 April 2019

Oncolytic viruses: a new class of immunotherapy drugs

scientific article published on September 2015

Oncolytic viruses: a new class of immunotherapy drugs

scientific article published on 01 August 2016

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses

scientific article published on 7 November 2013

Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer

scientific article published on 21 May 2020

Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface

scientific article

Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression

scientific article published on 17 June 2011

Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage response

scientific article

Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules

scientific article

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

scientific article published on 7 November 2013

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

scientific article published on 22 May 2019

Single-step nanoparticle antigen presentation system for tumor immunotherapy.

scientific article published on 4 November 2015

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.

scientific article published on 15 March 2016

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

scientific article

The impact of age on a mitoxantrone-based tumor vaccine

scientific article published on 7 November 2013

Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer.

scientific article published on 8 January 2018

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

scientific article published on 19 September 2017

List of works by Andrew Zloza

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma

ACTR-51. CLINICAL EVALUATION OF THE IMIPRIDONE ONC201 IN RECURRENT GLIOBLASTOMA: PREDICTIVE AND PHARMACODYNAMIC BIOMARKER ANALYSES

Active beta-catenin signaling is an inhibitory pathway for human immunodeficiency virus replication in peripheral blood mononuclear cells

Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy.

Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses

Beta-catenin signaling mediates CD4 expression on mature CD8+ T cells

Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease

CD11b activation suppresses TLR-dependent inflammation and autoimmunity in systemic lupus erythematosus

CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression

CD8(+) T cells sabotage their own memory potential through IFN-γ-dependent modification of the IL-12/IL-15 receptor α axis on dendritic cells.

CD8+ T cells that express CD4 on their surface (CD4dimCD8bright T cells) recognize an antigen-specific target, are detected in vivo, and can be productively infected by T-tropic HIV.

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth

DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS

Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor Xenografts

Editorial: Tumor Microenvironment and Resistance to Current Therapies

Engagement of NK receptor NKG2D, but not 2B4, results in self-reactive CD8+ T cells and autoimmune vitiligo

First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.

HIV Infection Leads to Redistribution of Leaky Claudin-2 in the Intestine of Humanized SCID IL-2R(-/-) Hu-PBMC Mice.

HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice

HSP70i is a critical component of the immune response leading to vitiligo

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis

IFN-lambda therapy: current status and future perspectives.

IFN-λ cancer immunotherapy: new kid on the block

IFN-λ: A New Inducer of Local Immunity against Cancer and Infections

Immune modulation of HIV replication: relevance to HIV immuno- and neuro-pathogenesis.

Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses

Infection: a Cause of and Cure for Cancer.

Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment

Interferon Lambda: Toward a Dual Role in Cancer

Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma.

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges

Multiple populations of T lymphocytes are distinguished by the level of CD4 and CD8 coexpression and require individual consideration.

Mutant HSP70 reverses autoimmune depigmentation in vitiligo

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade.

NKG2D signaling on CD8⁺ T cells represses T-bet and rescues CD4-unhelped CD8⁺ T cell memory recall but not effector responses

Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.

Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death.

Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.

Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.

Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

Oncolytic viruses: a new class of immunotherapy drugs

Oncolytic viruses: a new class of immunotherapy drugs

PD-1 blockade reverses viral infection-induced loss of anti-tumor CD8+ T cell responses

Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer

Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface

Priming with very low-affinity peptide ligands gives rise to CD8(+) T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression

Pro-inflammatory chemokine CCL2 (MCP-1) promotes healing in diabetic wounds by restoring the macrophage response

Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Single-step nanoparticle antigen presentation system for tumor immunotherapy.

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.

Talimogene laherparepvec (T-VEC) as cancer immunotherapy.

The impact of age on a mitoxantrone-based tumor vaccine

Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.